中国药理学与毒理学杂志
中國藥理學與毒理學雜誌
중국약이학여독이학잡지
CHINESE JOURNAL OF PHARMACOLOGY AND TOXICOLOGY
2015年
2期
179-190
,共12页
肿瘤%自噬%液泡分选蛋白34%自噬抑制剂
腫瘤%自噬%液泡分選蛋白34%自噬抑製劑
종류%자서%액포분선단백34%자서억제제
tumor%autophagy%vacuolar protein sorting 34%autophagy inhibitor
自噬是细胞清除并回收利用错误折叠的蛋白及受损细胞器而维持细胞稳态的分解代谢过程。这一过程与包括肿瘤在内的许多疾病有密切的关联,现已成为癌症研究的热点。自噬既具有肿瘤抑制功能,在化疗中又能保护肿瘤细胞。近年来,在自噬相关蛋白中,对自噬形成起到关键作用的液泡分选蛋白34(VPS34)受到了广泛关注,已和自噬一起成为肿瘤防治和抗肿瘤药物筛选靶标。最近,3个 VPS34的特异性抑制剂 PlK-Ⅲ,VPS34-lN1和 SAR405相继面世,它们可能对自噬的抑制及肿瘤干预具有独特的影响。本文介绍了自噬在肿瘤中扮演的不同角色和 VPS34在自噬中的功能调控,还讨论了以自噬及 VPS34为靶标的抑制剂研究最新进展及其在肿瘤防治中的应用前景。
自噬是細胞清除併迴收利用錯誤摺疊的蛋白及受損細胞器而維持細胞穩態的分解代謝過程。這一過程與包括腫瘤在內的許多疾病有密切的關聯,現已成為癌癥研究的熱點。自噬既具有腫瘤抑製功能,在化療中又能保護腫瘤細胞。近年來,在自噬相關蛋白中,對自噬形成起到關鍵作用的液泡分選蛋白34(VPS34)受到瞭廣汎關註,已和自噬一起成為腫瘤防治和抗腫瘤藥物篩選靶標。最近,3箇 VPS34的特異性抑製劑 PlK-Ⅲ,VPS34-lN1和 SAR405相繼麵世,它們可能對自噬的抑製及腫瘤榦預具有獨特的影響。本文介紹瞭自噬在腫瘤中扮縯的不同角色和 VPS34在自噬中的功能調控,還討論瞭以自噬及 VPS34為靶標的抑製劑研究最新進展及其在腫瘤防治中的應用前景。
자서시세포청제병회수이용착오절첩적단백급수손세포기이유지세포은태적분해대사과정。저일과정여포괄종류재내적허다질병유밀절적관련,현이성위암증연구적열점。자서기구유종류억제공능,재화료중우능보호종류세포。근년래,재자서상관단백중,대자서형성기도관건작용적액포분선단백34(VPS34)수도료엄범관주,이화자서일기성위종류방치화항종류약물사선파표。최근,3개 VPS34적특이성억제제 PlK-Ⅲ,VPS34-lN1화 SAR405상계면세,타문가능대자서적억제급종류간예구유독특적영향。본문개소료자서재종류중분연적불동각색화 VPS34재자서중적공능조공,환토론료이자서급 VPS34위파표적억제제연구최신진전급기재종류방치중적응용전경。
Autophagy is a catabolic process responsible for the degradation and recycling of misfolded proteins and damaged organelles for cellular homeostasis. This degradative pathway,closely related to many diseases including cancer,has become a focus of cancer research. lt can serve as a tumor suppressor,also functions as a protective cell-survival mechanism against chemotherapies. Of the autophagy-related proteins,vacuolar protein sorting 34(VPS34)has attracted major attention over the past decade because of its role in autophagic procedure. Recently,three specific inhibitors of VPS34,PlK-Ⅲ,VPSlN1 and SlR405,have been invented,showing unique implications for autophagy reduction and therapeutic benefit in tumor treatment. This paper summarizes the different roles of autophagy in clinical settings and the functional regulation of VPS34 upon post-translational modification and also discusses the application prospects of inhibitors targeting VPS34 or autophagy in cancer prevention and treatment.